Mxl (Morphine Sulfate)

Morphine Sulfate is an opioid analgesic used for pain management across several clinical settings.

• Post‑operative pain: reduces pain after surgical procedures
• Cancer pain: alleviates persistent pain associated with malignancy
• Chronic severe pain: provides analgesia when other treatments are insufficient

• Morphine Sulfate acts as a full agonist at the µ‑opioid receptors in the central nervous system. Binding to these G‑protein‑coupled receptors inhibits adenylate cyclase activity, reduces neuronal excitability, and decreases the release of excitatory neurotransmitters, resulting in analgesia and sedation.

Morphine Sulfate may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Nausea and vomiting: gastrointestinal upset common after initiation
• Constipation: reduced gastrointestinal motility leading to hard stools
• Drowsiness: sedation or fatigue, especially at higher doses
• Dry mouth: reduced salivation causing oral discomfort
• Pruritus: mild itching, often localized
• Urinary retention: difficulty initiating urination

Serious or Rare Side Effects

• Respiratory depression: slowed breathing that can be life‑threatening
• Severe hypotension: marked drop in blood pressure requiring medical attention
• Dependence or addiction: risk of misuse with prolonged therapy

When prescribing or dispensing Morphine Sulfate, consider the following safety measures.

• Assess pain severity: ensure opioid therapy is appropriate for moderate to severe pain
• Review medical history: identify respiratory disorders, head injury, or increased intracranial pressure
• Monitor for sedation: avoid operating machinery or driving until individual response is known
• Adjust for renal/hepatic impairment: dose may need reduction in organ dysfunction
• Avoid concomitant CNS depressants: limit use with benzodiazepines or alcohol
• Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light

Morphine Sulfate can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid)

• Other opioids: additive respiratory depression and profound sedation
• Benzodiazepines or barbiturates: synergistic CNS depression increasing overdose risk
• MAO inhibitors: can precipitate severe hypertension or serotonin syndrome

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma morphine levels
• CYP3A4 inducers (e.g., rifampin): may reduce analgesic effect
• Anticholinergics: may worsen constipation
• Diuretics: can enhance orthostatic hypotension
• Antidepressants (SSRIs/SNRIs): may increase risk of serotonin syndrome when combined with other serotonergic agents